ClinicalTrials.Veeva

Menu

Gene Expression in MS Patients Before and During Treatment With Interferon-beta

S

S. Andrea Hospital

Status

Terminated

Conditions

Multiple Sclerosis

Study type

Observational

Funder types

Other

Identifiers

NCT00202384
NEU - FCG - 02

Details and patient eligibility

About

Clinical and experimental evidences suggest that there is a variability in therapeutic response to immunomodulating therapies in Multiple Sclerosis patients.

Microarrays is a technology that permits to monitor the expression levels of thousands of genes at a time.

The specific aim of this study is to identify predictive factors of therapeutic response in MS patients treated with high-dose Interferon-Beta.

Enrollment

600 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • diagnosis of relapsing-remitting MS (McDonald criteria)
  • age between 18-55
  • EDSS less or equal to 5.5

Exclusion criteria

  • use of any other disease modifying drugs
  • use of corticosteroids during 3 months before starting protocol
  • clinical relapse during 1 month before starting protocol
  • serious heart, renal, hepatic or haematological dysfunction defined by laboratory exams

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems